[Infostock Daily= Reporter Lee Dong-hee] SAMSUNG BIOLOGICS announced on the 22nd that it signed a contract with GSK, a global pharmaceutical company, to produce consignment of biopharmaceuticals (CMO).
The total contract size is more than $231 million (about 283.9 billion won) over eight years.
SAMSUNG BIOLOGICS will be responsible for commercial production of Benista (component name Belimumab), which is expected to be the first commercial supply in 2022, starting with technology transfer this year. Production sizes could change at GSK's future request.
GSK expects the contract to further strengthen its existing production network.
"The contract with SAMSUNG BIOLOGICS will further complement and strengthen GSK's global pharmaceutical production capacity and help patients continue to provide innovative medicines they need," said Regis Simad, president of GSK's pharmaceutical purchasing division.
Kim Tae-han, president of SAMSUNG BIOLOGICS, said, "We have entered the biopharmaceutical industry to enable customers to supply biopharmaceuticals to patients faster." We are proud to announce a long-term contract with GSK. "
